KineMed is a biotechnology company that specializes in providing translational and personalized medicine. The company offers unparalleled insight into the complex biological processes underlying the root causes of disease. It uses the administration of stable (non-radioactive) isotopes to provide high-definition pharmacological measurements of disease activity and drug effects across a wide range of therapy areas, including diseases of the nervous system, metabolic and cardiovascular diseases, cancer, inflammation, and musculoskeletal diseases. It was founded in 2001 and headquartered in Emeryville, California.

Genervon is a clinical-stage biopharmaceutical company focused on novel treatments for neurodegenerative diseases and disorders.

Markets petroleum products and petrochemicals

Lascco focuses on biomedical technologies developed by scientists devoted to their academic activities and remote from the entrepreneurial world. Recent years have witnessed the emergence of a number of public and private organizations providing seed capital, management support, and sometimes infrastructure, for the launching of start-up biotech companies. These financial and business supports are primarily directed at scientists willing or ready to embark on an entrepreneurial venture. Innovative technologies developed by scientists devoted to their academic activities and uninterested in an entrepreneurial venture remain unexploited and their value is kept buried. They aim at filling the gap between academic research and the pharmaceutical industry, by structuring and managing the progression of selected discovery-stage biomedical technologies from the academic lab all the way to the proof of concept in humans. Their constant goal is to broaden their connections with the pharmaceutical industry and to remain well informed of the unmet market needs on the one hand, and to consolidate their relationship with researchers and physicians on the other hand.

UCB (Union Chimique Belge) is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with a revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's, and Crohn's diseases. The Company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system (CNS) disorders (including epilepsy), inflammatory disorders (including allergy), and oncology.

Schubert GmbH engages in the provision of electrical installation services. It manages installation projects in commercial and cultural buildings, hotels, and offices. The firm specializes in high and low voltage installations, lighting equipment, lightning protection and grounding systems, fire alarms, building automation, telecommunications installations, and information technology systems. The company is headquartered in Tangerhuette, Germany.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

SCHWARZ PHARMA, Inc. develops and manufactures pharmaceutical products. The company's products include Codimal, Colyte, Edex, Kutrase, Levatol, Robaxin, and Verelan. It was founded in 2003 and is headquartered in Mequon, WI.

Rhone Poulenc Rorer, a subsidiary of Solvay SA, is a French company that manufactures and distributs pharmaceutical products.

LTT Bio-Pharma Co. Ltd. engages in the research and development of drugs and new technologies. It also provides pharmaceuticals through drug delivery systems technology which delivers a required amount of drugs to the target site at the expected time; drug discovery; and dispensing pharmacy services. The company was founded by Yutaka Mizushima on April 1988 and is headquartered in Tokyo, Japan.

Shijiazhuang Yiling Pharmaceutical develops, produces, and sells patent medicines. The product portfolio includes traditional medicine, health care products, western formulations, and TCM slices, among others. They supply, introduce advanced equipment and pharmaceutical technology both domestically and internationally, and develop a quality control system.

Covis Pharma GmbH, part of Apollo Global Management, Inc., is a Swiss company that operates as a pharmaceutical company. The firm was acquired by Apollo Global Management, Inc. on February 06, 2020.

Hebei Yiling Pharmaceutical Research Institute Co., Ltd., established on 2001-04-19, Business scope includes Chinese patent medicine,Medicine and health products,Traditional Medical Devices,Western medicine,Biological product,Research and Development of Sanitary Dressing;technical consulting,Serve,transfer.(Those requiring special approval shall not operate without approval)

Toray Industries, Inc. (東レ株式会社 Tōre Kabushiki-gaisha) is a multinational corporation headquartered in Japan that specializes in industrial products centered on technologies in organic synthetic chemistry, polymer chemistry, and biochemistry.

Yeda Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science. Yeda holds an exclusive agreement with the Weizmann Institute to commercialize the unique intellectual property developed by the scientists. The income generated serves to support further basic research and science education. - Identify and assess research projects with commercial potential. - Protect the intellectual property of the Institute and its scientists. - Create business relationships and license the Institute’s inventions and technologies to the industry. - Channel funding from industry to research projects. For further information please contact Tamir Huberman, CIO and Head of Marketing